title: Treatment of psoriasis with rituximab.
authors.forename: Yu-Sheng
authors.initials: YS
authors.lastname: Chang
authors.forename: Hui-Ting
authors.initials: HT
authors.lastname: Lee
authors.forename: Wei-Sheng
authors.initials: WS
authors.lastname: Chen
authors.forename: Kai-Hung
authors.initials: KH
authors.lastname: Hsiao
authors.forename: Ming-Han
authors.initials: MH
authors.lastname: Chen
authors.forename: Chang-Youh
authors.initials: CY
authors.lastname: Tsai
authors.forename: Chung-Tei
authors.initials: CT
authors.lastname: Chou
mesh_terms: D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D011565:Psoriasis / Q000175:diagnosis* / Q000188:drug therapy*; D000069283:Rituximab; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab